FOXC1 Biomarker Assay for Cancer Recurrence Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer screening strategies fail to accurately predict which patients are at high risk of recurrence and metastasis, leading to diluted therapeutic efficacy in clinical trials and ineffective labeling of treatment approaches.
Innovation Solution
Utilizing FOXC1 as a biomarker to detect FOXC1 protein or nucleic acid levels in cancer patients, combined with targeted therapeutic strategies to inhibit FOXC1-driven pathways, to predict recurrence and metastasis risk and guide personalized treatment plans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical factors (TNM staging criteria) are used for cancer prognosis, then the diagnostic workflow remains simple and cost-effective, but the prediction accuracy for recurrence and metastasis risk is insufficient
Solution Approach 1:
The patent combines traditional clinical factors (TNM staging) with FOXC1 biomarker detection to create a composite diagnostic system. This merging approach allows the system to leverage both the simplicity of traditional criteria and the predictive power of molecular markers, achieving improved accuracy without completely redesigning the diagnostic workflow.
Solution Approach 2:
FOXC1 serves as an intermediary biomarker that bridges the gap between traditional clinical staging and actual cancer behavior. By detecting FOXC1 expression levels, the system can refine prognosis predictions for patients with the same TNM stage, providing more nuanced risk stratification while maintaining integration with existing diagnostic frameworks.
2Reliability
If new prognostic biomarkers are identified to improve recurrence prediction, then patient stratification and treatment selection improve, but the complexity of diagnostic workflows increases
Solution Approach 1:
The patent focuses on detecting changes in FOXC1 expression levels (a specific parameter) to stratify patients into different risk categories. By concentrating on this single biomarker parameter rather than multiple complex molecular profiles, the system achieves improved prognosis reliability while minimizing the increase in diagnostic workflow complexity.
3Measurement precision
If clinical trial populations are not enriched for high-risk patients, then trial enrollment remains accessible to broader populations, but therapeutic efficacy measurement is diluted
Solution Approach 1:
The system performs preliminary risk stratification using FOXC1 biomarker detection before patients are enrolled in clinical trials. This preliminary action identifies high-risk patients who are most likely to benefit from new therapies, allowing trial designers to proactively enroll these patients and ensure that efficacy measurements reflect the treatment's true impact on the most vulnerable population.
Data Source
AI summary
Antibodies for determining the level of FOXC1 protein in a subject's tumor and methods of using FOXC1 antibodies to predict clinical efficacy of a cancer therapeutic, predict prognosis of a subject receiving the cancer therapeutic, and treat the subject based on the predictions of clinical efficacy and prognosis.